Last update April 16, 2024

C20 H28 N2 O5


Safe substance and/or breastfeeding is the best option.

Enalapril is an angiotensin converting enzyme inhibitor (ACE inhibitor) used in the treatment of arterial hypertension and heart failure. Oral administration every 12-24 hours. 

It is excreted in breast milk in a clinically insignificant amount (Anderson 2018, Serrano 2015, Rush 1991, Redman 1990, Kirsten 1998, Huttunen 1989) and no problems have been observed in infants whose mothers took it (Anderson 2018, Rush 1991, Huttunen 1989), nor problems in establishing breastfeeding. (Bach 1995).

It is a licensed medication for use in young infants and, off-label, in neonates.(FDA 2018, Kirsten 1998). 

Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity.(Serrano 2015)

Expert authors and medical associations such as the American Academy of Pediatrics consider it a medication usually compatible with breastfeeding (Hale, LactMed, Ghelfi 2021, Serrano 2015, Rowe 2013, Dennis 2012, Ghanem 2008, AAP 2001, Kirsten 1998). 

The protective role of breastfeeding against maternal hypertension has been proven.(Park 2018).


  • Captopril (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C20 H28 N2 O5 is Enalapril in Molecular formula.

Is written in other languages:

C20 H28 N2 O5 is also known as


Main tradenames from several countries containing C20 H28 N2 O5 in its composition:


Variable Value Unit
Oral Bioavail. 60 %
Molecular weight 492 daltons
Protein Binding 60 %
VD 1.7 l/Kg
pKa 3.67 -
Tmax 1.5 hours
11 hours
M/P ratio 0.8 -
Theoretical Dose 0.0009 mg/Kg/d
Relative Dose 0.56 %
Ped.Relat.Dose 0.18 - 0.9 %


  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  3. Ghelfi AM, Ferretti MV, Staffieri GJ. Tratamiento farmacológico de la hipertensión arterial no severa durante el embarazo, el posparto y la lactancia. [Pharmacological treatment of non-severe hypertension during pregnancy, postpartum and breastfeeding]. Hipertens Riesgo Vasc. 2021 Feb 22. pii: S1889-1837(21)00013-1. Abstract
  4. FDA. Enalapril. Drug Summary. 2018 Full text (in our servers)
  5. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  6. Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Card Fail Rev. 2018 Abstract Full text (link to original source) Full text (in our servers)
  7. AEMPS. Enalapril. Ficha técnica. 2018 Full text (in our servers)
  8. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  9. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  10. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  11. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  12. Dennis AT. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia. 2012 Sep;67(9):1009-20. Abstract Full text (link to original source) Full text (in our servers)
  13. Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther. 2008 Abstract Full text (link to original source) Full text (in our servers)
  14. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  15. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract
  16. Bach N. [Enalapril treatment of a pre-eclamptic woman]. Ugeskr Laeger. 1995 Abstract
  17. Rush JE, Snyder DL, Barrish A, Hichens M. Comment on Huttunen K, Grönhagen-Riska C and Fyhrquist F, 1989. Enalapril treatment of a nursing mother with slightly impaired renal function. Clin Nephrol 31: 278. Clin Nephrol. 1991 Abstract
  18. Redman CW, Kelly JG, Cooper WD. The excretion of enalapril and enalaprilat in human breast milk. Eur J Clin Pharmacol. 1990 Abstract
  19. Huttunen K, Grönhagen-Riska C, Fyhrquist F. Enalapril treatment of a nursing with slightly impaired renal function. Clin Nephrol. 1989 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM